Performance and predictors of minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab

By Coates LC, Abraham S, Tillett W, et al
Published September 16, 2020

Key Takeaways

This study was undertaken to investigate concurrent validity and discrimination of modified minimal disease activity (mMDA) criteria in peripheral spondyloarthritis (pSpA) following OMERACT filter principles and determine predictors of mMDA response. The ABILITY‐2 study derived four mMDA versions applying the Spondyloarthritis Research Consortium of Canada or Leeds Enthesitis Index (LEI) but excluding psoriasis.  Researchers assessed treatment discrimination between adalimumab and placebo at week 12. They applied multiple logistic regression to ascertain baseline predictors of long‐term mMDA responses and sustained mMDA. The results demonstrate that all four versions of mMDA exhibited concurrent validity and discriminated well between adalimumab and placebo treatment groups. It was shown that early mMDA response is a more consistent prognosticator of long‐term mMDA achievement than baseline characteristics. In pSpA patients, the 5 of 6 versions of mMDA could be an appropriate treatment target.

Read the full article on Arthritis Care & Research .

Share with emailShare to FacebookShare to LinkedInShare to Twitter
ADVERTISEMENT